Key Takeaways
- • Pathos AI closed a $237 million Series E financing round at a post-money valuation of approximately $3 billion, according to the company's announcement.
- • Bristol Myers Squibb led the round, with participation from existing investors.
- • Pathos describes itself as a clinical-stage AI and technology company that develops its own therapeutic pipeline rather than solely licensing AI tools to drugmakers.
- • The company's pipeline spans clinical-stage programs in metastatic castration-resistant prostate cancer, multiple myeloma, MET-altered non-small-cell lung cancer, ER+/HER2 breast cancer, and TROP2/HER3-expressing solid tumors.
Summary
Pathos AI, a New York-based clinical-stage AI and technology company, announced the closing of a $237 million Series E financing round at a post-money valuation of approximately $3 billion. The round was led by Bristol Myers Squibb, with participation from existing investors. The announcement was made in a company press release datelined New York.
Pathos positions itself as a drug developer that applies artificial intelligence across the development process. According to the company, it redesigns drug development from first principles, identifying clinical assets, making portfolio decisions using continuously updated probability-of-success calculations, and guiding clinical trials with AI-native monitoring. This approach places the company in the business of owning and advancing its own therapeutic pipeline rather than acting solely as a technology vendor to pharmaceutical partners.
The company's clinical-stage pipeline includes programs in metastatic castration-resistant prostate cancer, multiple myeloma, MET-altered non-small-cell lung cancer, ER+/HER2 breast cancer, and TROP2/HER3-expressing solid tumors. The breadth of indications reflects the company's portfolio-based model. The source material does not disclose the amount of capital allocated to individual programs, trial timelines, or the use of proceeds beyond general pipeline advancement.
Bristol Myers Squibb's role as lead investor is the most notable element of the financing for institutional observers, as it signals strategic interest from a large pharmaceutical company in AI-driven drug development at a valuation of roughly $3 billion. Investors should note that the post-money valuation figure is company-reported and approximate.
Pathos positions itself as a drug developer that applies artificial intelligence across the development process. According to the company, it redesigns drug development from first principles, identifying clinical assets, making portfolio decisions using continuously updated probability-of-success calculations, and guiding clinical trials with AI-native monitoring. This approach places the company in the business of owning and advancing its own therapeutic pipeline rather than acting solely as a technology vendor to pharmaceutical partners.
The company's clinical-stage pipeline includes programs in metastatic castration-resistant prostate cancer, multiple myeloma, MET-altered non-small-cell lung cancer, ER+/HER2 breast cancer, and TROP2/HER3-expressing solid tumors. The breadth of indications reflects the company's portfolio-based model. The source material does not disclose the amount of capital allocated to individual programs, trial timelines, or the use of proceeds beyond general pipeline advancement.
Bristol Myers Squibb's role as lead investor is the most notable element of the financing for institutional observers, as it signals strategic interest from a large pharmaceutical company in AI-driven drug development at a valuation of roughly $3 billion. Investors should note that the post-money valuation figure is company-reported and approximate.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.